Total Hip Arthroplasty (THA)E1vsMarNCT04126421
Vitamin E Polyethylene in Semented Cups
A study testing Prosthesis component (acetabular cup) E1 cup and Prosthesis component (acetabular cup) Marathon cup in people with Total Hip Arthroplasty (THA), run by Oslo University Hospital at 1 site in Norway.
Trial summary
A prospective randomized controlled study evaluating the wear and migration of cemented acetabular sockets with third generation highly cross-linked vitamin E infused polyethylene and second generation highly crosslinked UHMWPE using Radiostereometric Analysis (RSA). Read more about this study
- Who is it for?
- Ages Up to 74 years
- Conditions the study is for
- Total Hip Arthroplasty (THA)
- What is being tested?
- Prosthesis component (acetabular cup) E1 cup and Prosthesis component (acetabular cup) Marathon cup
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 68 participants
- Where
- 1 siteNorway
- Study dates
- 1 Apr 2011to 1 Jun 2019
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 74 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- patients under the age of 75 with primary or secondary arthrosis scheduled for total hip arthroplasty.
Who cannot join
- a major anatomical deviation, immunosuppressive medication or a significant systemic disease.
Trial locations and contacts
1 site in 1 country.
Norway1 site
Division of Orthopedic Surgery, Oslo Univsersity Hospital
Oslo, 0850
About this study
Official title: Vitamin E Stabilized Highly Cross-linked Polyethylene in Reversed Hybrid Total Hip
A prospective randomized controlled study evaluating the wear and migration of cemented acetabular sockets with third generation highly cross-linked vitamin E infused polyethylene and second generation highly crosslinked UHMWPE using Radiostereometric Analysis (RSA).
Read the detailed description
Background Reducing the rate of polyethylene (PE) wear in acetabular sockets and thereby increasing the lifespan of Total Hip Arthroplasty (THA) has been a major concern in the orthopaedic community for decades. Wear of PE and osteolysis followed by late aseptic loosening of the prosthesis is the main reason for revision surgery after THA in Norway.
During 2008 in Norway 805 out of a total of 1114 revised THA were subjugated to surgery due to aseptic loosening or osteolysis without loosening. The DRG (Diagnose Related Grouping) weight is 5.49 for secondary THA and every DRG point has a value of 33.647 NOK adding up to a direct total cost for revision after aseptic loosening of approximately 27 million USD.
Caput prosthesis with a diameter of 32mm or more has the major advantage to increase the Range of Motion (ROM) and to reduce the risk of dislocation of the hip but, the larger the caput prosthesis the more adhesive wear can be expected. This and the relative failure of metal on PE gave the incentive to develop and take into clinical practise bearings with increased resilience to wear. Today, there exists a wide range of options with a substantially lower rate of volumetric wear compared to conventional PE. The biological and immunological in vivo response to wear particles is very complicated and only partially understood. It is clear that host response to wear particles and the corrosion products play a major role in osteolysis around the prosthesis. For metal-on-metal (MoM) bearings the volumetric wear is a magnitude less but the number of particle debris is massively increased. MoM also have the problem with possible teratogen effect and allergy or hypersensitivity side effects. Ceramic on ceramic (cer-cer) has the lowest wear rate of any artificial articulations, but it is still possible to detect biologically active debris particles. Cer-cer also has other challenges including fracture of prosthesis, squeaking hip, narrow margins for placing components and cost.
Polyethylene is a thermoplastic polymer consisting of long chains of the monomer ethylene (C2H4). The mechanical properties of PE depend on variables such as the extent and type of branching and the crystal structure etc.
To improve the wear resistance of the PE an increase in the cross-linking between the chains of polyethylene can be achieved by exposing it to high-energy irradiation. The irradiation also increases the unpaired free electrons (free radicals). Free radicals can react with oxygen and start a chain reaction causing an oxidative degradation of the polyethylene and consequently cause increased wear. 1st generation HXLPE sockets have reduced the mid term incidence of particle-induced osteolysis but retrieved failed first-generation HXLPE sockets have shown surface cracking and signs of in vivo oxidative degradation.
In order to enhance the resistance to mechanical fatigue and reduce oxidative potential 2nd generation HXLPE was developed. To reduce the oxidative potential the polyethylene can be remelted or annealed. Remelting aggravates the mechanical properties of the polyethylene and after annealing there are still remaining free radicals capable of oxidation in vivo. By binding to unpaired free electrons Vitamin E is a scavenger of free radicals. Vitamin E is hydrophobic and can thereby be infused into polyethylene. 3rd generation HXLPE is manufactured below the melting temperature to maintain its mechanical properties and contains Vitamin E to stabilize free radicals. Uncemented Acetabular HXLPE sockets have been shown to have substantially reduced volumetric wear and excellent clinical mid-term results with this type of PE. In Scandinavia the majority of sockets are cemented. The different principles of biological or mechanical stability affects the properties of the socket typically different E-module and the surrounding interface between implant and bone. Conventional PE cemented cups have performed better with less aseptic loosening than uncemented cups. However, as the mechanical properties are changed in highly cross-linked Polyethylene cups, it is not clear whether the higher elasticity of the bone-cement-polyethylene compound might lead to fractures of the more brittle polyethylene. It is therefore not possible to extrapolate clinical results and wear rates from uncemented cups to cemented ones.
Placement of the cup is a crucial parameter for wear and cup survival. Malchau et al. has shown that even high volume surgeons achieve suboptimal placement in 40% of cases. This may depend on patient positioning perioperative, surgical instruments or technique. It is not known whether the surgeon's subjective operative technique directly corresponds to the postoperative evaluation of the cups position. However, adequate cup positioning is crucial in the evaluation of wear. CT is the best method to judge cup position postoperatively and detect osteolysis in the long time perspective.
To the investigators knowledge no randomized controlled study of cemented 3rd generation HXLPE cups utilizing RSA has been conducted.
Hypothesis There is a mid term in vivo reduction of volumetric polyethylene wear with cemented acetabular socket 3rd generation E1™ HXLPE compared with 2nd generation HXLPE.
Material: 70 eligible patients will be included following written informed consent. The participants will be randomized by the envelope method to either E1™ or Marathon™ cemented acetabular socket. The surgery will be performed at the hospitals in Vestre Viken HF and Oslo University hospital HF, Ullevål ortopeden.
Implant The investigators will use two different cemented all PE acetabular sockets;
- MarathonTM is a 1st generation HXLPE. The polyethylene is cross-linked with 5 Mrad that corresponds to a semi cross-linked PE.
- The E1™ cemented is an all PE Vitamin E stabilized 3rd generation highly crosslinked UHMWPE. In vitro tests have shown a 99 % decreased volumetric wear rate comparing E1™ with ArComXL™ HXLPE, (highly crosslinked polyethylene) under high contact stress and a 95% reduction in wear rate comparing E1™ with ArCom™ under high contact area stress. Wear particle morphology of E1™ is similar to that of the ArCom™ material.
Collared Corail™ (De Puy, Warsaw, Indiana, USA) uncemented femoral prosthesis is a titanium tapered implant fully coated with 150 micron hydroxyapatite with over 95% survival after 15 years. The caput prosthesis used is the Cobalt Chrome 32 mm Articul/EZE™ (De Puy, Warsaw, Indiana, USA) Refobacin ™ (Biomet Europe, Berlin, Germany) Bone Cement R is a high viscosity, x-ray positive bone cement. A sachet of 40 g Refobacin® Bone Cement R contains 0.5 g gentamicin.
Surgical technique The patient is operated in the position after surgeon's preference and under spinal anaesthesia. Accordingly the approach is after surgeon's preference. When posterolateral approach is chosen a repair of the capsule and the external rotators should be performed. Peroperatively a total of 6 1,0mm tantalum beads are implanted in the perimeter of the socket and 7 beads in the acetabulum. The acetabular socket is positioned as close to 45◦ abduction and 30◦ anteversion as possible.
The surgeon will postoperative directly grade cup position subjectively as anteverted, neutral, retroverted, proximalized, distalized.
Postoperative training Postoperatively the patient is mobilized with full weight bearing from day one.
Radiological analyses Conventional x-ray of pelvis, anterioposterior and lateral projections of hip preoperatively, postoperatively and at 24 (60, 120) months RSA (Radiostereometric analysis) postoperatively, 3, 12, 24 (60, 120) months, the RSA will be analysed at Ullevål University Hospital
Clinical Control Harris Hip Score, EQ-5D and WOMAC will be filled out preoperatively and at 2, 5 and 10 years.
Analysis of data RSA analysis will be performed at the Centre of Implant and Radiostereometric Research Oslo (CIRRO).
The study analysis is conducted under the guidance of CIRRO.
Storage of data Data will be collected and stored at the server for research at Oslo University Hospital. All data is stored anonymously. Each patient receives a study ID. The randomisation key and identity is stored separately.
Statistics Penetration of more than 0,1 mm annually in polyethylene articulations indicates a wear rate that will lead to future osteolysis1.
Scientific value Firstly, if recently developed manufacturing techniques of polyethylene can be shown to decrease the wear rate in vivo, and otherwise have a good clinical and radiological outcome, we have the reason to believe we have the possibility of significantly reducing the revision rate after THA.
Secondly, new implants should thoroughly be investigated and documented before widespread use. This could save many patients from possible disastrous failures as the past has taught us (Boneloc, Carbon compressed Poly).
Safety for the patient. The investigators will follow the normal routines for THA pre, per and postoperatively. Standardized routines in regards to infection and thrombosis prophylaxis following the recommendations from the Norwegian national board of orthopaedics will be followed. Implantation of Tantalum beads has been shown to have negligible side effects.
The E1TM and Marathon PE is clinically tested in uncemented THA, the other components of the prosthesis has more than 10 years clinical and RSA documentation.
Biomet will cover expenses including:
Extra cost of purchasing and storing prosthesis compared with standard prosthesis. Biomet or Stryker has no copy right or any other form of ownership to the result of this study.
- Conditions
- Total Hip Arthroplasty (THA)
- Being tested
- Prosthesis component (acetabular cup) E1 cup, Prosthesis component (acetabular cup) Marathon cup
- Keywords
- Highly cross-linked polyethylene (HXLPE), Vitamin E infused polyethylene
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Prosthesis component (acetabular cup) E1 cupDevice
Also called E1 cup
Semented acetabuar cup With E1 cup
Prosthesis component (acetabular cup) Marathon cupDevice
Also called Marathon cup
Semented acetabuar cup With Marathon cup
| Study group | Role | What they receive |
|---|---|---|
| E1 Vitamin E infused HXLPE | Active comparator | E1 Vitamin E infused highly cross-linked polyethylene (HXLPE) Receives: Device: Prosthesis component (acetabular cup) E1 cup |
| Marathon HXLPE | Active comparator | Marathon highly cross-linked polyethylene (HXLPE) Receives: Device: Prosthesis component (acetabular cup) Marathon cup |
What is being measured
The primary outcome is the main question the study is designed to answer.
Migration of prothesis components
Migration of prothesis components using radiosterometric analysis of hip x-rays (RSA)
Measured: 5 years
Secondary outcomes (4)
HHS (Patient reported outcome measure (PROMs))
Harris Hip Score (scale from 0-100, 100 being the best score/result)
Measured: 10 years
EQ-5D (Patient reported outcome measure (PROMs))
EQ-5D (5 health status descriptions (mobility, self-care, usual activites, pain/discomfort, anxiety/depression) rated by 3 level scale for all categories (1=no problems, 2=moderate problems, 3=extreme problems), in addition there is a health evaluation by VAS scale 0-100, 100 being the worst)
Measured: 10 years
WOMAC (Patient reported outcome measure (PROMs))
WOMAC (5 items for pain 0-20 (higher score being worse), 2 for stiffness 0-80 (higher score being worse), 17 for functional outcomes 0-68 (higher score being worse))
Measured: 10 years
VAS pain (Patient reported outcome measure (PROMs))
Visual analog scale (VAS) for pain (scale from 0-10, 10 being the worst pain)
Measured: 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Oct 2019
- Study start1 Apr 2011
- Primary completion1 Jun 2019
- Study completion1 Jun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (15)Papers the sponsor has linked to this study.
- Other trials for Total Hip Arthroplasty (THA)Studies of the same condition, open and under way.
- More trials run by Oslo University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized controlled trial (RCT). Randomized to either E1 semented cup or Marathon semented cup in total hip arthroplasty (THA).
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 68 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oslo University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of Oslo
- Responsible party
- Principal investigator, Peder Svenkerud Thoen, Oslo University Hospital
- Investigators
- Stephan M Röhrl, PhD, MD, Study chair, Division of Orthopedic Surgery, Oslo University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04126421
- Sponsor's protocol ID
- 2010/2621a
- Acronym
- E1vsMar
- Status last verified
- Jan 2020
- First submitted
- 29 Sep 2019
- Last updated
- 7 Jan 2020
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Digas G, Karrholm J, Thanner J, Malchau H, Herberts P. The Otto Aufranc Award. Highly cross-linked polyethylene in total hip arthroplasty: randomized evaluation of penetration rate in cemented and uncemented sockets using radiostereometric analysis. Clin Orthop Relat Res. 2004 Dec;(429):6-16.
PubMed 15577460Kjærsgaard-Andersen 2010 Orthopaedics today
The Norwegian Arthroplasty Register, 2009
Garcia-Cimbrelo E, Munuera L. Early and late loosening of the acetabular cup after low-friction arthroplasty. J Bone Joint Surg Am. 1992 Sep;74(8):1119-29.
PubMed 1400540Barrack RL, Folgueras A, Munn B, Tvetden D, Sharkey P. Pelvic lysis and polyethylene wear at 5-8 years in an uncemented total hip. Clin Orthop Relat Res. 1997 Feb;(335):211-7.
PubMed 9020220Tarasevicius S, Robertsson O, Kesteris U, Kalesinskas RJ, Wingstrand H. Effect of femoral head size on polyethylene wear and synovitis after total hip arthroplasty: a sonographic and radiographic study of 39 patients. Acta Orthop. 2008 Aug;79(4):489-93. doi: 10.1080/17453670710015472.
PubMed 18766481Harris WH, Muratoglu OK. A review of current cross-linked polyethylenes used in total joint arthroplasty. Clin Orthop Relat Res. 2005 Jan;(430):46-52. doi: 10.1097/01.blo.0000152603.58384.e9.
PubMed 15662303Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic science. Clin Orthop Relat Res. 2001 Dec;(393):71-7. doi: 10.1097/00003086-200112000-00008.
PubMed 11764373Doorn PF, Campbell PA, Worrall J, Benya PD, McKellop HA, Amstutz HC. Metal wear particle characterization from metal on metal total hip replacements: transmission electron microscopy study of periprosthetic tissues and isolated particles. J Biomed Mater Res. 1998 Oct;42(1):103-11. doi: 10.1002/(sici)1097-4636(199810)42:13.0.co;2-m.
PubMed 9740012Campbell DG, Field JR, Callary SA. Second-generation highly cross-linked X3 polyethylene wear: a preliminary radiostereometric analysis study. Clin Orthop Relat Res. 2010 Oct;468(10):2704-9. doi: 10.1007/s11999-010-1259-y. Epub 2010 Feb 12.
PubMed 20151231Ries MD, Pruitt L. Effect of cross-linking on the microstructure and mechanical properties of ultra-high molecular weight polyethylene. Clin Orthop Relat Res. 2005 Nov;440:149-56. doi: 10.1097/01.blo.0000185310.59202.e5.
PubMed 16239799Bitsch RG, Loidolt T, Heisel C, Ball S, Schmalzried TP. Reduction of osteolysis with use of Marathon cross-linked polyethylene. A concise follow-up, at a minimum of five years, of a previous report. J Bone Joint Surg Am. 2008 Jul;90(7):1487-91. doi: 10.2106/JBJS.F.00991.
PubMed 18594097Rohrl S, Nivbrant B, Mingguo L, Hewitt B. In vivo wear and migration of highly cross-linked polyethylene cups a radiostereometry analysis study. J Arthroplasty. 2005 Jun;20(4):409-13. doi: 10.1016/j.arth.2004.09.040.
PubMed 16124954Rohrl SM, Li MG, Nilsson KG, Nivbrant B. Very low wear of non-remelted highly cross-linked polyethylene cups: an RSA study lasting up to 6 years. Acta Orthop. 2007 Dec;78(6):739-45. doi: 10.1080/17453670710014509.
PubMed 18236179Malchau H. Revision total hip arthroplasty. Failure mechanisms and outcomes. Orthopedics. 1996 Sep;19(9):769-70. doi: 10.3928/0147-7447-19960901-17. No abstract available.
PubMed 8887419
Study at a glance
From the registry record, last updated by the sponsor on 7 Jan 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Vitamin E Stabilized Highly Cross-linked Polyethylene in Reversed Hybrid Total Hip
- ClinicalTrials.gov ID
- NCT04126421
- Acronym / sponsor ID
- E1vsMar / 2010/2621a
- Conditions
- Total Hip Arthroplasty (THA)
- Keywords
- Highly cross-linked polyethylene (HXLPE), Vitamin E infused polyethylene
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 68 participants (actual)
- Lead sponsor
- Oslo University HospitalUniversity, hospital or other
- Collaborators
- University of Oslo
- Study start
- 1 Apr 2011 (actual)
- Primary completion
- 1 Jun 2019 (actual)
- Study completion
- 1 Jun 2019 (actual)
- First posted
- 15 Oct 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A prospective randomized controlled study evaluating the wear and migration of cemented acetabular sockets with third generation highly cross-linked vitamin E infused polyethylene and second generation highly crosslinked UHMWPE using Radiostereometric Analysis (RSA).
Detailed description
Background Reducing the rate of polyethylene (PE) wear in acetabular sockets and thereby increasing the lifespan of Total Hip Arthroplasty (THA) has been a major concern in the orthopaedic community for decades. Wear of PE and osteolysis followed by late aseptic loosening of the prosthesis is the main reason for revision surgery after THA in Norway.
During 2008 in Norway 805 out of a total of 1114 revised THA were subjugated to surgery due to aseptic loosening or osteolysis without loosening. The DRG (Diagnose Related Grouping) weight is 5.49 for secondary THA and every DRG point has a value of 33.647 NOK adding up to a direct total cost for revision after aseptic loosening of approximately 27 million USD.
Caput prosthesis with a diameter of 32mm or more has the major advantage to increase the Range of Motion (ROM) and to reduce the risk of dislocation of the hip but, the larger the caput prosthesis the more adhesive wear can be expected. This and the relative failure of metal on PE gave the incentive to develop and take into clinical practise bearings with increased resilience to wear. Today, there exists a wide range of options with a substantially lower rate of volumetric wear compared to conventional PE. The biological and immunological in vivo response to wear particles is very complicated and only partially understood. It is clear that host response to wear particles and the corrosion products play a major role in osteolysis around the prosthesis. For metal-on-metal (MoM) bearings the volumetric wear is a magnitude less but the number of particle debris is massively increased. MoM also have the problem with possible teratogen effect and allergy or hypersensitivity side effects. Ceramic on ceramic (cer-cer) has the lowest wear rate of any artificial articulations, but it is still possible to detect biologically active debris particles. Cer-cer also has other challenges including fracture of prosthesis, squeaking hip, narrow margins for placing components and cost.
Polyethylene is a thermoplastic polymer consisting of long chains of the monomer ethylene (C2H4). The mechanical properties of PE depend on variables such as the extent and type of branching and the crystal structure etc.
To improve the wear resistance of the PE an increase in the cross-linking between the chains of polyethylene can be achieved by exposing it to high-energy irradiation. The irradiation also increases the unpaired free electrons (free radicals). Free radicals can react with oxygen and start a chain reaction causing an oxidative degradation of the polyethylene and consequently cause increased wear. 1st generation HXLPE sockets have reduced the mid term incidence of particle-induced osteolysis but retrieved failed first-generation HXLPE sockets have shown surface cracking and signs of in vivo oxidative degradation.
In order to enhance the resistance to mechanical fatigue and reduce oxidative potential 2nd generation HXLPE was developed. To reduce the oxidative potential the polyethylene can be remelted or annealed. Remelting aggravates the mechanical properties of the polyethylene and after annealing there are still remaining free radicals capable of oxidation in vivo. By binding to unpaired free electrons Vitamin E is a scavenger of free radicals. Vitamin E is hydrophobic and can thereby be infused into polyethylene. 3rd generation HXLPE is manufactured below the melting temperature to maintain its mechanical properties and contains Vitamin E to stabilize free radicals. Uncemented Acetabular HXLPE sockets have been shown to have substantially reduced volumetric wear and excellent clinical mid-term results with this type of PE. In Scandinavia the majority of sockets are cemented. The different principles of biological or mechanical stability affects the properties of the socket typically different E-module and the surrounding interface between implant and bone. Conventional PE cemented cups have performed better with less aseptic loosening than uncemented cups. However, as the mechanical properties are changed in highly cross-linked Polyethylene cups, it is not clear whether the higher elasticity of the bone-cement-polyethylene compound might lead to fractures of the more brittle polyethylene. It is therefore not possible to extrapolate clinical results and wear rates from uncemented cups to cemented ones.
Placement of the cup is a crucial parameter for wear and cup survival. Malchau et al. has shown that even high volume surgeons achieve suboptimal placement in 40% of cases. This may depend on patient positioning perioperative, surgical instruments or technique. It is not known whether the surgeon's subjective operative technique directly corresponds to the postoperative evaluation of the cups position. However, adequate cup positioning is crucial in the evaluation of wear. CT is the best method to judge cup position postoperatively and detect osteolysis in the long time perspective.
To the investigators knowledge no randomized controlled study of cemented 3rd generation HXLPE cups utilizing RSA has been conducted.
Hypothesis There is a mid term in vivo reduction of volumetric polyethylene wear with cemented acetabular socket 3rd generation E1™ HXLPE compared with 2nd generation HXLPE.
Material: 70 eligible patients will be included following written informed consent. The participants will be randomized by the envelope method to either E1™ or Marathon™ cemented acetabular socket. The surgery will be performed at the hospitals in Vestre Viken HF and Oslo University hospital HF, Ullevål ortopeden.
Implant The investigators will use two different cemented all PE acetabular sockets;
- MarathonTM is a 1st generation HXLPE. The polyethylene is cross-linked with 5 Mrad that corresponds to a semi cross-linked PE.
- The E1™ cemented is an all PE Vitamin E stabilized 3rd generation highly crosslinked UHMWPE. In vitro tests have shown a 99 % decreased volumetric wear rate comparing E1™ with ArComXL™ HXLPE, (highly crosslinked polyethylene) under high contact stress and a 95% reduction in wear rate comparing E1™ with ArCom™ under high contact area stress. Wear particle morphology of E1™ is similar to that of the ArCom™ material.
Collared Corail™ (De Puy, Warsaw, Indiana, USA) uncemented femoral prosthesis is a titanium tapered implant fully coated with 150 micron hydroxyapatite with over 95% survival after 15 years. The caput prosthesis used is the Cobalt Chrome 32 mm Articul/EZE™ (De Puy, Warsaw, Indiana, USA) Refobacin ™ (Biomet Europe, Berlin, Germany) Bone Cement R is a high viscosity, x-ray positive bone cement. A sachet of 40 g Refobacin® Bone Cement R contains 0.5 g gentamicin.
Surgical technique The patient is operated in the position after surgeon's preference and under spinal anaesthesia. Accordingly the approach is after surgeon's preference. When posterolateral approach is chosen a repair of the capsule and the external rotators should be performed. Peroperatively a total of 6 1,0mm tantalum beads are implanted in the perimeter of the socket and 7 beads in the acetabulum. The acetabular socket is positioned as close to 45◦ abduction and 30◦ anteversion as possible.
The surgeon will postoperative directly grade cup position subjectively as anteverted, neutral, retroverted, proximalized, distalized.
Postoperative training Postoperatively the patient is mobilized with full weight bearing from day one.
Radiological analyses Conventional x-ray of pelvis, anterioposterior and lateral projections of hip preoperatively, postoperatively and at 24 (60, 120) months RSA (Radiostereometric analysis) postoperatively, 3, 12, 24 (60, 120) months, the RSA will be analysed at Ullevål University Hospital
Clinical Control Harris Hip Score, EQ-5D and WOMAC will be filled out preoperatively and at 2, 5 and 10 years.
Analysis of data RSA analysis will be performed at the Centre of Implant and Radiostereometric Research Oslo (CIRRO).
The study analysis is conducted under the guidance of CIRRO.
Storage of data Data will be collected and stored at the server for research at Oslo University Hospital. All data is stored anonymously. Each patient receives a study ID. The randomisation key and identity is stored separately.
Statistics Penetration of more than 0,1 mm annually in polyethylene articulations indicates a wear rate that will lead to future osteolysis1.
Scientific value Firstly, if recently developed manufacturing techniques of polyethylene can be shown to decrease the wear rate in vivo, and otherwise have a good clinical and radiological outcome, we have the reason to believe we have the possibility of significantly reducing the revision rate after THA.
Secondly, new implants should thoroughly be investigated and documented before widespread use. This could save many patients from possible disastrous failures as the past has taught us (Boneloc, Carbon compressed Poly).
Safety for the patient. The investigators will follow the normal routines for THA pre, per and postoperatively. Standardized routines in regards to infection and thrombosis prophylaxis following the recommendations from the Norwegian national board of orthopaedics will be followed. Implantation of Tantalum beads has been shown to have negligible side effects.
The E1TM and Marathon PE is clinically tested in uncemented THA, the other components of the prosthesis has more than 10 years clinical and RSA documentation.
Biomet will cover expenses including:
Extra cost of purchasing and storing prosthesis compared with standard prosthesis. Biomet or Stryker has no copy right or any other form of ownership to the result of this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 2
- Model description
- Randomized controlled trial (RCT). Randomized to either E1 semented cup or Marathon semented cup in total hip arthroplasty (THA).
| Arm | Type | Receives |
|---|---|---|
| E1 Vitamin E infused HXLPE | Active comparator | Device: Prosthesis component (acetabular cup) E1 cupE1 Vitamin E infused highly cross-linked polyethylene (HXLPE) |
| Marathon HXLPE | Active comparator | Device: Prosthesis component (acetabular cup) Marathon cupMarathon highly cross-linked polyethylene (HXLPE) |
Who may qualify
- Ages
- Up to 74 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- patients under the age of 75 with primary or secondary arthrosis scheduled for total hip arthroplasty.
Key exclusion criteria (1 listed)
- a major anatomical deviation, immunosuppressive medication or a significant systemic disease.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Prosthesis component (acetabular cup) E1 cupAlso: E1 cupSemented acetabuar cup With E1 cup | Device | E1 Vitamin E infused HXLPE |
| Prosthesis component (acetabular cup) Marathon cupAlso: Marathon cupSemented acetabuar cup With Marathon cup | Device | Marathon HXLPE |
Primary outcome
Migration of prothesis components
Time frame: 5 years
Migration of prothesis components using radiosterometric analysis of hip x-rays (RSA)
4 secondary outcomes
HHS (Patient reported outcome measure (PROMs))
Time frame: 10 years
EQ-5D (Patient reported outcome measure (PROMs))
Time frame: 10 years
WOMAC (Patient reported outcome measure (PROMs))
Time frame: 10 years
VAS pain (Patient reported outcome measure (PROMs))
Time frame: 10 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jan 2020.
- Background: PubMed 15577460Digas G, Karrholm J, Thanner J, Malchau H, Herberts P. The Otto Aufranc Award. Highly cross-linked polyethylene in total hip arthroplasty: randomized evaluation of penetration rate in cemented and uncemented sockets using radiostereometric analysis. Clin Orthop Relat Res. 2004 Dec;(429):6-16.
- BackgroundKjærsgaard-Andersen 2010 Orthopaedics today
- BackgroundThe Norwegian Arthroplasty Register, 2009
- Background: PubMed 1400540Garcia-Cimbrelo E, Munuera L. Early and late loosening of the acetabular cup after low-friction arthroplasty. J Bone Joint Surg Am. 1992 Sep;74(8):1119-29.
- Background: PubMed 9020220Barrack RL, Folgueras A, Munn B, Tvetden D, Sharkey P. Pelvic lysis and polyethylene wear at 5-8 years in an uncemented total hip. Clin Orthop Relat Res. 1997 Feb;(335):211-7.
- Background: PubMed 18766481Tarasevicius S, Robertsson O, Kesteris U, Kalesinskas RJ, Wingstrand H. Effect of femoral head size on polyethylene wear and synovitis after total hip arthroplasty: a sonographic and radiographic study of 39 patients. Acta Orthop. 2008 Aug;79(4):489-93. doi: 10.1080/17453670710015472.
- Background: PubMed 15662303Harris WH, Muratoglu OK. A review of current cross-linked polyethylenes used in total joint arthroplasty. Clin Orthop Relat Res. 2005 Jan;(430):46-52. doi: 10.1097/01.blo.0000152603.58384.e9.
- Background: PubMed 11764373Jacobs JJ, Roebuck KA, Archibeck M, Hallab NJ, Glant TT. Osteolysis: basic science. Clin Orthop Relat Res. 2001 Dec;(393):71-7. doi: 10.1097/00003086-200112000-00008.
- Background: PubMed 9740012Doorn PF, Campbell PA, Worrall J, Benya PD, McKellop HA, Amstutz HC. Metal wear particle characterization from metal on metal total hip replacements: transmission electron microscopy study of periprosthetic tissues and isolated particles. J Biomed Mater Res. 1998 Oct;42(1):103-11. doi: 10.1002/(sici)1097-4636(199810)42:13.0.co;2-m.
- Background: PubMed 20151231Campbell DG, Field JR, Callary SA. Second-generation highly cross-linked X3 polyethylene wear: a preliminary radiostereometric analysis study. Clin Orthop Relat Res. 2010 Oct;468(10):2704-9. doi: 10.1007/s11999-010-1259-y. Epub 2010 Feb 12.
- Background: PubMed 16239799Ries MD, Pruitt L. Effect of cross-linking on the microstructure and mechanical properties of ultra-high molecular weight polyethylene. Clin Orthop Relat Res. 2005 Nov;440:149-56. doi: 10.1097/01.blo.0000185310.59202.e5.
- Background: PubMed 18594097Bitsch RG, Loidolt T, Heisel C, Ball S, Schmalzried TP. Reduction of osteolysis with use of Marathon cross-linked polyethylene. A concise follow-up, at a minimum of five years, of a previous report. J Bone Joint Surg Am. 2008 Jul;90(7):1487-91. doi: 10.2106/JBJS.F.00991.
- Individual participant dataSharing planned: No
Related trials for Total Hip Arthroplasty (THA)
Enrolling by invitationPhase 2
Efficacy of Intravenous Oxytocin to Speed Recovery After THA
Total Hip Arthroplasty
Enrolling by invitationPhase 3
A Clinical Trial Evaluating the Efficacy and Safety of Local Infiltration of RF16001 for Injection for Analgesia After Total Hip Arthroplasty in China
Pain After Abdominal Surgery
RecruitingObservational study
Mpact 3D Metal Monolit Study
Total Hip Arthroplasty (THA)
Recruiting
Pre-Op THA Modelling
Total Hip Arthroplasty, Computer-Assisted Surgery
RecruitingPhase 4
Post-op Prednisone and Glucose Monitoring in TKA
Osteoarthritis, Unicompartmental Knee Arthroplasty
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephan M Röhrl, PhD, MD study chair
Division of Orthopedic Surgery, Oslo University Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Prosthesis component (acetabular cup) E1 cup and Prosthesis component (acetabular cup) Marathon cup in people with Total Hip Arthroplasty (THA), run by Oslo University Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jan 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Migration of prothesis components (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04126421, which also lists 15 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jan 2020.